Specific Phobia

According to the DSM-IV, Specific Phobia is a marked and persistent fear of specific objects or situations. Exposure to that stimulus almost always provokes anxiety. This reaction may resemble a panic attack, which has symptoms such as heightened heart rate, sweating, hyperventilation (rapid, shallow breathing) and feelings of terror and helplessness.

Adolescents and adults usually recognize that this fear is excessive or unreasonable. This often results in avoidance of the feared stimulus, although sometimes it can be endured with great discomfort. This diagnosis only applies if the avoidance or anticipation anxiety interferes in the person's daily functioning or holding a job, their social life, or if they are distressed about having the phobia.

The subtypes of specific phobia are:

Treatment

The Institute treats specific phobias using Exposure Response Prevention Therapy and cognitive components implemented through talk therapy, writing exercises, loop tapes and narratives, customized for the phobia of the individual patient.

Source: Page 444, DSM-IV, Year 2005, American Psychiatric Association

Announcements & Upcoming Events

LACPA 2012 Brown Bag Lecture January 9, 2012 LACPA Office

Dr. Gorbis will be lecturing on the "Comorbidity of OCD and Eating Disorders and its Implication to Treatment" to members of the LA County Psychological Association. She will be addressing the issue of comorbidity of OCD and eating disorders and the implications of each disorders in terms of etiology as well as treatment.

Medical research study of an investigational medicine for patients with OCD who have not responded to treatment with SSRIs

To pre-qualify for this study, patients must be at least 18 yrs. old, have a documented diagnosis of OCD as defined by the DSM-IV-TR, have been taking one of the following SSRIs for at least six weeks prior to screening and at the minimum daily dosage listed: fuvoxamine (Luvox®) 200 mg, fluoxetine (Prozac®) 40 mg, paroxetine (Paxil®) 40 mg, sertraline (Zoloft®) 100 mg. The study is expected to last about 20 weeks. Each patient will receive study medication and study-related medical evaluations at no cost. Reimbursement for travel may also be provided. Please contact us for additional eligibility requirements.

[Admin: Update]